The commercial opportunity is to develop antagonists of Rspo2 and/or Rspo3 for the treatment of Sdc(Syndecan)-associated disorders and for Sdc antagonists in the treatment of Rspo2- and/or Rspo3-associated disorders.
Further Information: PDF
Deutsches Krebsforschungszentrum DKFZ
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
